Biologics manufacturing is becoming an important area of the global biotechnology industry. Pharmaceutical companies are investing in production capacity, developing manufacturing partnerships, and improving the processes used to make complex biological medicines. These developments are important because biologics are used to treat a wide range of conditions, including cancer, autoimmune diseases, and rare genetic disorders.
Recent biologics manufacturing news highlights the growing role of contract development and manufacturing organizations (CDMOs), biosimilar production, and regulatory oversight. In October 2026, LOTTE Biologics and Alvotech announced a long-term manufacturing partnership in the United States. The agreement is one example of how biotechnology companies are working together to support medicine production and expand supply capabilities.
This article examines recent industry developments, how biologics are manufactured, the role of manufacturing technology, and the quality standards that pharmaceutical companies must follow.
Latest Biologics Manufacturing News in 2026
One notable development came on October 8, 2026, when LOTTE Biologics and Alvotech announced a long-term strategic manufacturing partnership. According to the announcement, LOTTE Biologics will manufacture drug substance for multiple antibody biosimilar products at its Syracuse, New York, facility.
The companies said the partnership is intended to increase global manufacturing capacity and support growing demand for biosimilar medicines. The Syracuse facility has 40,000 liters of bioreactor capacity, alongside process development and quality control capabilities.
The agreement also gives Alvotech additional access to manufacturing capacity in the United States. However, the announcement does not establish a specific number of additional doses that will be produced or guarantee that every product in development will reach the market.
Read the partnership announcement from LOTTE Biologics and Alvotech.
FDA Approves Additional Manufacturing Capacity for a Biosimilar
Another important development occurred on October 5, 2026, when Alvotech announced that the U.S. Food and Drug Administration (FDA) had approved an additional manufacturing suite for Simlandi, its biosimilar to Humira.
The approval allows the company to manufacture the drug substance for U.S. commercial supply in a second production suite at its Reykjavik facility in Iceland.
According to Alvotech, this additional suite doubles the drug substance manufacturing capacity available to support U.S. supply of the product. It also provides greater flexibility by allowing production for the U.S. market in either of the two approved suites.
This development illustrates how regulatory approval of manufacturing facilities can affect the availability and flexibility of medicine production. It does not mean that the drug’s total worldwide supply has automatically doubled.
Read the official Alvotech announcement about the additional manufacturing capacity.
What Is Biologics Manufacturing?
Biologics manufacturing is the process of producing medicines using living cells or biological systems. Unlike many traditional small-molecule drugs, biologics are complex products that may contain proteins, antibodies, or other substances produced through biological processes.
Examples of biologic medicines include:
- Monoclonal antibodies used in cancer treatment and immune-related conditions.
- Recombinant proteins used to replace or supplement proteins in the body.
- Certain vaccines that help prevent infectious diseases.
- Therapeutic proteins used for specific rare diseases.
- Some advanced therapies made from cells or genetic material.
Manufacturing methods vary depending on the product. Companies must develop a process that consistently produces the intended biological substance with the required quality, purity, and activity.
How Are Biologic Medicines Manufactured?
Biologics manufacturing generally involves several connected stages. The precise process depends on the type of medicine and its manufacturing platform.
1. Cell Line Development
For many recombinant biologics, scientists develop or select cells that can produce the desired protein. These cells are carefully characterized and maintained to support consistent production.
The choice of cell line can affect product quality, manufacturing performance, and the development timeline.
2. Cell Culture and Bioreactor Production
Cells are grown under controlled conditions in specialized vessels called bioreactors. Manufacturers monitor factors such as temperature, pH, oxygen levels, nutrients, and mixing to maintain appropriate growth and production conditions.
Bioreactor size varies by product and facility. Large-scale production can require substantial infrastructure, trained personnel, and careful process control.
3. Harvesting and Purification
After production, the desired biological substance is collected and purified. Depending on the product, purification can involve filtration, chromatography, and other separation methods.
The objective is to remove unwanted materials while preserving the quality and activity of the intended product.
4. Formulation and Filling
The purified substance is prepared in a suitable formulation. It may then be filled into vials, prefilled syringes, or other approved delivery systems.
Manufacturers must control contamination risks and ensure that containers protect the product throughout its shelf life.
5. Quality Testing and Release
Biologic products undergo testing to assess identity, purity, potency, and other product-specific quality characteristics. Manufacturers also evaluate whether the production process remains consistent with approved specifications.
A batch is released for distribution only after the applicable quality requirements have been met.
Why Are Companies Investing in Biologics Manufacturing?
Several factors influence investment in biologics manufacturing.
Growing Demand for Complex Medicines
Biologics are used in many therapeutic areas, and some products require specialized manufacturing processes. Companies may expand capacity when expected demand, product pipelines, or supply requirements justify the investment.
However, demand varies by medicine and market. Not every biologic product requires a new facility or an increase in production capacity.
Expansion of Biosimilar Production
Biosimilars are biological products that have been demonstrated to be highly similar to an approved reference biologic, with no clinically meaningful differences in safety, purity, and potency under applicable regulatory standards.
Developing and manufacturing biosimilars can require significant technical expertise. Companies must establish appropriate analytical methods, demonstrate similarity, and meet relevant regulatory requirements.
The LOTTE Biologics and Alvotech partnership is an example of companies collaborating to support the production of antibody biosimilars.
Manufacturing Partnerships
Some biotechnology companies use CDMOs to support process development, scale-up, and commercial production. This can provide access to established manufacturing infrastructure and technical expertise without requiring every company to build and operate all facilities itself.
Partnerships can also help companies diversify production locations. Nevertheless, outsourcing does not remove a medicine manufacturer’s responsibility to ensure appropriate product quality and regulatory compliance.
How the FDA Oversees Biologics Manufacturing
The FDA regulates biologics intended for the U.S. market and evaluates manufacturing information as part of its regulatory review.
Manufacturers must follow applicable current good manufacturing practice (CGMP) requirements. These requirements address areas such as facilities, equipment, quality systems, production controls, records, and testing.
The FDA may inspect manufacturing facilities to assess whether operations comply with applicable standards and whether the facility can consistently produce products meeting required quality specifications.
In June 2026, the FDA announced seven participants in its PreCheck Pilot Program, which is intended to support the development of new domestic pharmaceutical manufacturing facilities through earlier engagement with the agency.
The selected companies included Eli Lilly, Regeneron, Amneal, Cellares, Fujifilm Biotechnologies, Kriya Therapeutics, and Kyowa Kirin. The program covers different manufacturing categories, including biologics and advanced therapies.
The program is not a blanket approval for participating companies’ products or facilities. Individual products and manufacturing sites remain subject to applicable regulatory requirements.
For further information, consult the FDA’s official drug manufacturing initiatives and its biologics manufacturing guidance resources.
Challenges in Biologics Manufacturing
Despite advances in biotechnology, biologics manufacturing remains technically demanding.
Maintaining Consistent Product Quality
Biological products can be sensitive to changes in raw materials, process conditions, and handling. Manufacturers must understand and control these variables to maintain consistency between batches.
Managing Production Costs
Specialized equipment, quality testing, skilled employees, and regulatory compliance can make biologics manufacturing expensive. Companies must balance production costs with quality requirements and the need for a reliable supply.
Scaling Up Production
A process that works at a small research scale may behave differently when transferred to a larger manufacturing system. Companies must evaluate scale-up carefully and demonstrate that the larger process can consistently produce an acceptable product.
Preventing Contamination
Microbial contamination and other unwanted materials can compromise product quality. Appropriate facility design, cleaning procedures, environmental monitoring, and process controls are important parts of manufacturing operations.
What Is the Future of Biologics Manufacturing?
The future of biologics manufacturing will depend on scientific progress, investment decisions, regulatory requirements, and demand for individual medicines.
Several areas are worth watching:
- Process automation: Digital monitoring and automated controls may help manufacturers track production conditions and manage complex operations.
- Single-use technologies: Disposable manufacturing equipment can reduce some cleaning requirements, although it introduces its own material, waste, and supply considerations.
- Manufacturing capacity expansion: Partnerships and new facilities may help companies respond to specific supply needs.
- Analytical technology: Improved testing methods can help characterize complex products and monitor manufacturing consistency.
- Supply chain resilience: Multiple qualified production sites may offer additional flexibility when one location experiences disruption.
These technologies do not automatically improve every manufacturing process. Their value depends on the product, the production system, validation, and the ability to maintain consistent quality.
Frequently Asked Questions About Biologics Manufacturing News
What is the latest biologics manufacturing news in 2026?
On October 8, 2026, LOTTE Biologics and Alvotech announced a long-term manufacturing partnership involving antibody biosimilar drug substance production at LOTTE Biologics’ Syracuse, New York, facility. Alvotech also announced FDA approval for an additional Simlandi manufacturing suite on October 5, 2026.
What is a biologics manufacturing facility?
A biologics manufacturing facility is a specialized site designed to produce biological medicines. Depending on its purpose, it may contain cell culture systems, purification equipment, formulation and filling lines, laboratories, and quality control operations.
What is the difference between biologics and biosimilars?
Biologics are medicines produced using biological systems or substances. Biosimilars are biological products developed to be highly similar to an already approved reference biologic, with no clinically meaningful differences in safety, purity, and potency under applicable standards.
Why do pharmaceutical companies use CDMOs?
Companies use contract development and manufacturing organizations to access specialized equipment, technical expertise, process development services, and manufacturing capacity. The arrangement can support development or commercial production, depending on the agreement.
How does the FDA ensure biologics manufacturing quality?
The FDA reviews relevant manufacturing information, establishes applicable regulatory requirements, and inspects facilities when appropriate. Manufacturers must maintain quality systems and demonstrate that their products meet applicable standards.
Is biologics manufacturing growing?
Investment and partnerships in biologics manufacturing continue to be reported, but growth varies by product category, company, and region. Individual announcements should be evaluated separately rather than treated as proof of uniform growth across the entire industry.
Conclusion
Biologics manufacturing news in 2026 highlights the importance of production capacity, manufacturing partnerships, biosimilar development, and regulatory oversight. The LOTTE Biologics–Alvotech agreement and the additional FDA-approved manufacturing suite for Simlandi illustrate two different approaches to supporting medicine supply.
As biological medicines become more complex, manufacturers must balance production efficiency with rigorous quality controls. New facilities, partnerships, and technologies may provide additional capacity and flexibility, but their long-term impact depends on execution, regulatory compliance, and demand for specific medicines.
For the latest developments, readers should follow official company announcements, FDA updates, and reliable biotechnology industry publications. Confirming dates, regulatory decisions, and production claims against primary sources helps readers understand what has actually changed in biologics manufacturing.
Leave a Reply